Physician profile
Ziad Sous
NPI 1336102284
$1,253.18
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $339 · 2021: $106.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $237.05 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $180.74 | 2019-2021 | |
| Pfizer INC. | $171.94 | 2019-2021 | |
| Inari Medical, INC. | $161.63 | 2020 | |
| Silk Road Medical, INC. | $153.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $119.76 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $48.11 | 2019 | |
| Allergan, INC. | $36.01 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.79 | 2019 | |
| Shire North American Group INC | $21.41 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.21 | 2020 | |
| Paratek Pharmaceuticals, INC. | $20.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.61 | 2019 | |
| Abbvie INC. | $15.12 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.62 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $14.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ziad Sous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.